FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to oncology, and can be used to predict progression in colorectal cancer. Tumour tissue is sampled, RNA is extracted from tumour tissue and gene combination is determined. If observing high expression of ZDHHC11, MIR4432HG genes and low expression of GZMB gene, disease progression is predicted.
EFFECT: method provides effective prediction of progression in colorectal cancer by determining expression of genes ZDHHC11, MIR4432HG and GZMB in tumour tissue.
1 cl, 3 dwg, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR DETERMINATION OF RISK OF BREAST ONCOLOGICAL DISEASES RECURRENCE | 2015 |
|
RU2626603C2 |
| METHOD OF PREDICTING METASTASIS OF STOMACH CANCER TUMORS | 2021 |
|
RU2806432C2 |
| TEST-CLASSIFIER OF THE CLINICAL RESPONSE TO TREATMENT WITH SORAFENIB IN INDIVIDUAL PATIENTS WITH KIDNEY CANCER | 2018 |
|
RU2747746C2 |
| SET OF REAGENTS FOR DETERMINING THE RISK OF RECURRENCE OF BREAST CANCER | 2017 |
|
RU2671557C1 |
| METHOD OF DETERMINING PROBABILITY OF RECURRENT BREAST CANCER | 2014 |
|
RU2609199C2 |
| METHOD FOR PREDICTION OF OUTCOME IN PATIENTS WITH GASTRIC CANCER AFTER COMBINED TREATMENT, INCLUDING NEOADJUVANT CHEMOTHERAPY ACCORDING TO FOLFOX6 OR FLOT REGIMENS AND SURGICAL TREATMENT | 2024 |
|
RU2831907C1 |
| TEST SYSTEM “miR-M-SCREEN” FOR PREDICTING THE DEVELOPMENT OF METASTASES IN PATIENTS WITH COLORECTAL CANCER BASED ON THE LEVEL OF miR-26a AND miR-143 MICRO-RNA IN BLOOD PLASMA | 2022 |
|
RU2786386C1 |
| METHOD FOR PREDICTION OF LIVER METASTASES IN PATIENTS WITH COLON CANCER | 2018 |
|
RU2686687C1 |
| METHODS FOR CLASSIFYING PATIENTS WITH SOLID CANCER | 2017 |
|
RU2745730C2 |
| METHOD FOR PREDICTION OF SURVIVAL IN PATIENTS WITH CLEAR CELL RENAL CELL CARCINOMA | 2018 |
|
RU2699792C1 |
